Carregant...
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma A Review
IMPORTANCE: For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and several immune checkpoint blockers (ICBs) that hav...
Guardat en:
| Publicat a: | JAMA Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8265820/ https://ncbi.nlm.nih.gov/pubmed/33090190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3381 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|